Share on StockTwits

Research analysts at Cowen and Company boosted their price objective on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $276.00 to $285.00 in a report released on Friday, Analyst Ratings.Net reports. The firm currently has a “market perform” rating on the stock. Cowen and Company’s price target suggests a potential upside of 2.00% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at UBS AG reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. They now have a $320.00 price target on the stock, up previously from $310.00. Separately, analysts at Robert W. Baird raised their price target on shares of Regeneron Pharmaceuticals from $362.00 to $368.00 in a research note on Monday. Finally, analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 30th. They now have a $359.00 price target on the stock. Nine analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $347.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.64% during mid-day trading on Friday, hitting $279.41. 877,228 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 1-year low of $206.30 and a 1-year high of $352.49. The stock has a 50-day moving average of $296.6 and a 200-day moving average of $296.6. The company has a market cap of $27.703 billion and a P/E ratio of 73.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 8th. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the prior year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $9.87 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.